scispace - formally typeset
A

André D'Hoore

Researcher at Katholieke Universiteit Leuven

Publications -  334
Citations -  17699

André D'Hoore is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Medicine & Colectomy. The author has an hindex of 52, co-authored 295 publications receiving 14676 citations. Previous affiliations of André D'Hoore include University of Amsterdam & Universitaire Ziekenhuizen Leuven.

Papers
More filters
Journal ArticleDOI

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

TL;DR: This paper is the second in a series of three publications relating to the European evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the management of active disease, maintenance of medically induced remission and surgery.
Journal ArticleDOI

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

TL;DR: The most widely used index for severe UC remains that of Truelove and Witts3: any patient who has a bloody stool frequency ≥ 6/day and a tachycardia (> 90 bpm), or temperature > 37.8 °C, or anaemia (haemoglobin 30 mm/h) has severe ulcerative colitis (Table 1.3) as mentioned in this paper.
Journal ArticleDOI

Long-term outcome of laparoscopic ventral rectopexy for total rectal prolapse.

TL;DR: The aim of this study was to assess the long‐term outcome of patients who underwent a novel, autonomic nerve‐sparing, laparoscopic technique for rectal prolapse.
Journal ArticleDOI

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

TL;DR: Although the authors did not observe differences in adverse effects on the short term, the use of 2 mg/kg IV cyclosporine should provide an improved toxicity profile for medical treatment of severe UC.